These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 33134483)

  • 41. Hepatology consultation is associated with decreased early return to alcohol use after discharge from an inpatient alcohol use disorder treatment program.
    Blaney HL; Khalid MB; Yang AH; Asif BA; Vittal A; Kamal N; Wright EC; Abijo T; Koh C; George D; Goldman D; Horneffer Y; Diazgranados N; Heller T
    Hepatol Commun; 2024 May; 8(5):. PubMed ID: 38619432
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A longitudinal examination of alcohol pharmacotherapy adoption in substance use disorder treatment programs: patterns of sustainability and discontinuation.
    Abraham AJ; Knudsen HK; Roman PM
    J Stud Alcohol Drugs; 2011 Jul; 72(4):669-77. PubMed ID: 21683049
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Patient perspectives on alcohol use disorder pharmacotherapy and integration of treatment into primary care settings.
    Haley SJ; Pinsker EA; Gerould H; Wisdom JP; Hagedorn HJ
    Subst Abus; 2019; 40(4):501-509. PubMed ID: 30829127
    [No Abstract]   [Full Text] [Related]  

  • 44. Medication Utilization for Alcohol Use Disorder in a Commercially Insured Population.
    Huskamp HA; Reif S; Greenfield SF; Normand ST; Busch AB
    J Gen Intern Med; 2020 Nov; 35(11):3262-3270. PubMed ID: 32754780
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Hepatology and the Canadian gastroenterologist: interest, attitudes and patterns of practice: results of a national survey from the Canadian Association of Gastroenterology.
    Bain VG; Wong WW; Greig PD; Yoshida EM;
    Can J Gastroenterol; 2003 Jan; 17(1):25-9. PubMed ID: 12560851
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Barriers to and facilitators of pharmacotherapy for alcohol use disorder in VA residential treatment programs.
    Finlay AK; Ellerbe LS; Wong JJ; Timko C; Rubinsky AD; Gupta S; Bowe TR; Burden JL; Harris AHS
    J Subst Abuse Treat; 2017 Jun; 77():38-43. PubMed ID: 28476269
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Alcohol use disorder in alcohol-associated liver disease: Two sides of the same coin.
    Singal AK; Leggio L; DiMartini A
    Liver Transpl; 2024 Feb; 30(2):200-212. PubMed ID: 37934047
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Medications for treating alcohol use disorder: A narrative review.
    Kranzler HR; Hartwell EE
    Alcohol Clin Exp Res (Hoboken); 2023 Jul; 47(7):1224-1237. PubMed ID: 37526592
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Beliefs and attitudes about prescribing opioids among healthcare providers seeking continuing medical education.
    Hooten WM; Bruce BK
    J Opioid Manag; 2011; 7(6):417-24. PubMed ID: 22320023
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Training of hepatology providers improves the screening and resultant interventions for alcohol use disorder.
    Saraireh H; Redman J; Abdelfattah T; Mangray S; Wade JB; Gilles HS; Fuchs M; Morris A; Malpaya Z; Puri P; Davis BC; Patel SS; Bajaj JS
    Liver Int; 2020 Sep; 40(9):2090-2094. PubMed ID: 32633900
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The relationship of antidepressant prescribing concentration to treatment duration and cost.
    Hodgkin D; Merrick EL; Hiatt D
    J Ment Health Policy Econ; 2012 Mar; 15(1):3-11. PubMed ID: 22611088
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Off-label baclofen prescribing practices among French alcohol specialists: results of a national online survey.
    Rolland B; Paille F; Fleury B; Cottencin O; Benyamina A; Aubin HJ
    PLoS One; 2014; 9(6):e98062. PubMed ID: 24887094
    [TBL] [Abstract][Full Text] [Related]  

  • 53. How a Medication for Opioid Use Disorder Curriculum Translates into Experiences and Internal Medicine Residents' Understanding of Patients with Opioid Use Disorder.
    Robles M; Mortazavi L; Vannerson J; Matthias MS
    Teach Learn Med; 2022; 34(5):514-521. PubMed ID: 33974460
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Assessing Naltrexone Prescribing and Barriers to Initiation for Alcohol Use Disorder: A Multidisciplinary, Multisite Survey.
    Leung JG; Narayanan PP; Markota M; Miller NE; Philbrick KL; Burton MC; Kirchoff RW
    Front Psychiatry; 2022; 13():856938. PubMed ID: 35619618
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Using clinical decision support through the electronic medical record to increase prescribing of high-dose parenteral thiamine in hospitalized patients with alcohol use disorder.
    Wai JM; Aloezos C; Mowrey WB; Baron SW; Cregin R; Forman HL
    J Subst Abuse Treat; 2019 Apr; 99():117-123. PubMed ID: 30797383
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Diagnosis and Pharmacotherapy of Alcohol Use Disorder: A Review.
    Kranzler HR; Soyka M
    JAMA; 2018 Aug; 320(8):815-824. PubMed ID: 30167705
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Attitudes, beliefs, and practices among Swiss chiropractors regarding medication prescribing for musculoskeletal conditions: a national Q-methodology study.
    Emary PC; Oremus M; Houweling TAW; Wangler M; Akhtar-Danesh N
    Chiropr Man Therap; 2020 Oct; 28(1):54. PubMed ID: 33076943
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A gender-focused perspective on health service utilization in comorbid bipolar I disorder and alcohol use disorders: results from the national epidemiologic survey on alcohol and related conditions.
    Goldstein BI; Levitt AJ
    J Clin Psychiatry; 2006 Jun; 67(6):925-32. PubMed ID: 16848652
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Prescribing patterns and attitudes of primary care providers regarding long-term opioid therapy.
    Koch NV; Butterfield Iii RJ
    J Opioid Manag; 2022; 18(5):407-420. PubMed ID: 36226781
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Alcohol Use Disorder Treatment: Problems and Solutions.
    Koob GF
    Annu Rev Pharmacol Toxicol; 2024 Jan; 64():255-275. PubMed ID: 38261428
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.